Trade-Ideas LLC identified DexCom ( DXCM) as a post-market laggard candidate. In addition to specific proprietary factors, Trade-Ideas identified DexCom as such a stock due to the following factors:

  • DXCM has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $54.2 million.
  • DXCM is down 2.3% today from today's close.

EXCLUSIVE OFFER: Get the inside scoop on opportunities in DXCM with the Ticky from Trade-Ideas. See the FREE profile for DXCM NOW at Trade-Ideas

More details on DXCM: DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring systems in the United States and internationally. Currently there are 11 analysts that rate DexCom a buy, 1 analyst rates it a sell, and 2 rate it a hold. The average volume for DexCom has been 933,000 shares per day over the past 30 days. DexCom has a market cap of $5.4 billion and is part of the health care sector and health services industry. The stock has a beta of 0.25 and a short float of 3.7% with 3.33 days to cover. Shares are down 23% year-to-date as of the close of trading on Tuesday.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

TheStreetRatings.com

Analysis:

TheStreet Quant Ratings

rates DexCom as a

sell

. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, disappointing return on equity, weak operating cash flow and feeble growth in its earnings per share. Highlights from the ratings report include:

  • The company, on the basis of change in net income from the same quarter one year ago, has significantly underperformed when compared to that of the S&P 500 and the Health Care Equipment & Supplies industry. The net income has significantly decreased by 48.8% when compared to the same quarter one year ago, falling from -$12.90 million to -$19.20 million.
  • Return on equity has greatly decreased when compared to its ROE from the same quarter one year prior. This is a signal of major weakness within the corporation. Compared to other companies in the Health Care Equipment & Supplies industry and the overall market, DEXCOM INC's return on equity significantly trails that of both the industry average and the S&P 500.
  • Net operating cash flow has significantly decreased to -$0.20 million or 105.88% when compared to the same quarter last year. In addition, when comparing to the industry average, the firm's growth rate is much lower.
  • DEXCOM INC's earnings per share declined by 35.3% in the most recent quarter compared to the same quarter a year ago. The company has reported a trend of declining earnings per share over the past two years. However, the consensus estimate suggests that this trend should reverse in the coming year. During the past fiscal year, DEXCOM INC reported poor results of -$0.73 versus -$0.32 in the prior year. This year, the market expects an improvement in earnings (-$0.34 versus -$0.73).
  • After a year of stock price fluctuations, the net result is that DXCM's price has not changed very much. Although its weak earnings growth may have played a role in this flat result, don't lose sight of the fact that the performance of the overall market, as measured by the S&P 500 Index, was essentially similar. The fact that the stock is now selling for less than others in its industry in relation to its current earnings is not reason enough to justify a buy rating at this time.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.